EXPLORE EVIDENCE
Clinical validation
study results
Percepta GSC clinical validation study design and results
Percepta GSC was validated in a prospective, multicenter, blinded study on a combined cohort of 412 patients from AEGIS I, AEGIS II and PERCEPTA Registry.1
Percepta GSC stratifies the risk of primary lung cancer across all pre-test risk groups to guide patient management when bronchoscopy is inconclusive.
For intermediate pre-test risk patients, Percepta GSC can down-classify or up-classify.
For intermediate pre-test risk patients with an inconclusive bronchoscopy, Percepta GSC can down-classify the risk of primary lung cancer to low with a 91% NPV to help avoid additional invasive procedures or up-classify the risk to high with a 65% PPV to inform next intervention steps.2
Percepta GSC improves the sensitivity of bronchoscopy regardless of nodule size, location, and cancer type.3
Percepta GSC detects genomic changes to determine if a nodule is cancerous without the need to directly sample the nodule.
Using whole-transcriptome RNA sequencing technology Percepta GSC is clinically validated with a combined cohort from AEGIS I and II & PERCEPTA Registry.
Hear from peers
Discover what key opinion leaders are saying about Percepta GSC in case studies, testimonials or on-demand presentations.
References
1. Choi Y, et al. BMC Medical Genomics, 2020.
2. Mazzone P, et al. Oral Presentation CHEST Annual Meeting 2019.
3. Dotson T, et al. Virtual e-poster, ATS Annual Meeting 2020.
